Skip to main content

Table 1 Trials characteristics

From: A systematic review and network meta-analysis comparing azacitidine and decitabine for the treatment of myelodysplastic syndrome

Author, year

Intervention (dose, schedule)

Comparison (description)

Patients (N)

Age (years)

Male (%)

IPSS classification intervention

IPSS classification comparison

Follow-up (months)

Azacitidine

 Fenaux, 2009 [10]

Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q 28 days for at least six cycles

BSC, low-dose Ara-C 20 mg/m2, intensive chemotherapy, or mitoxantrone

Intervention: 179

Comparison: 179

Intervention: 69 (42–83)

Comparison: 70 (38–88)

NR

Intermediate-1: 5 (3%)

Intermediate-2: 76 (43%)

High: 82 (46%)

Intermediate-1: 13 (7%)

Intermediate-2: 70 (39%)

High: 85 (48%)

42

 Silverman, 2002 [19]

Azacitidine: subcutaneously 75 mg/m2/day for 7 days Q 28 days for at least six cycles

Supportive care with antibiotics and transfusions

Intervention: 99

Comparison: 92

Intervention: 69 (31–92)

Comparison: 67 (35–88)

Intervention: 71.05

Comparison: 63.27

Low*: 2 (2%)

Intermediate-1: 21 (26%)

Intermediate-2: 9 (11%)

High: 7 (9%)

Low*: 5 (6%)

Intermediate-1: 16 (20%)

Intermediate-2: 13 (16%)

High: 8 (10%)

53

Decitabine

 Kantarjian, 2006 [21]

Decitabine: intravenously 15 mg/m2 Q 8 h for 3 days, every 6 weeks

BSC

Intervention: 89

Comparison: 81

Intervention: 70 (65–76)

Comparison: 70 (62–74)

Intervention: 66.29

Comparison: 70.37

Intermediate-1: 28 (31%)

Intermediate-2: 38 (43%)

High: 23 (26%)

Intermediate-1: 24 (30%)

Intermediate-2: 36 (44%)

High: 21 (26%)

30

 Lubbert, 2011 [11]

Decitabine: intravenously 15 mg/m2 Q 8 h for 3 days, every 6 weeks

BSC

Intervention: 119

Comparison: 114

Intervention: 69 (60–90)

Comparison: 70 (60–86)

Intervention: 63.87

Comparison: 64.04

Intermediate-1: 8 (6.7%)

Intermediate-2: 64 (53.8%)

High: 46 (38.7%)

Intermediate-1: 8 (7%)

Intermediate-2: 63 (55.3%)

High: 42 (36.8%)

30

  1. BSC best supportive care, IPSS International Prognostic Scoring System, N total number of patients
  2. *Data reported on 81 patients